BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Week In Review | Feb 22, 2019
Clinical News

FDA issues handful of new PDUFA dates

With the government shutdown resolved, FDA has accepted a handful of applications for review during the beginning Feb. 18, according to company announcements. FDA granted Priority Review to two applications from Genentech Inc. for entrectinib...
BC Extra | Feb 19, 2019
Company News

FDA issues handful of new PDUFA dates

With the government shutdown resolved, FDA has accepted a handful of applications for review, according to company announcements early this week. FDA granted Priority Review to two applications from Genentech Inc. for entrectinib and polatuzumab...
BC Extra | Aug 16, 2018
Company News

Management tracks: Achillion, Navidea

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) hired Anthony Gibney as EVP and CBO. He was managing director and co-head of the biotechnology investment banking team at Leerink Partners. Immunotherapy company Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB;...
BC Week In Review | Nov 18, 2016
Clinical News

Biosimilar teriparatide regulatory update

EMA's CHMP recommended approval of Terrosa/Movymia, a biosimilar of osteoporosis drug Forsteo teriparatide from Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.). The biosimilar is under review to treat osteoporosis in postmenopausal women and in men...
Items per page:
1 - 5 of 5